Comment of ‘Subsequent primary cancer incidence in cervical cancer survivors: insights from a comprehensive cohort study utilizing combined Japanese population-based cancer registries’
Journal of Gynecologic Oncology · 2026 · 37
DOI: 10.3802/jgo.2026.37.e133 ↗Kurz gefasst
Kommentar in der Zeitschrift Journal of Gynecologic Oncology, 2026. Verfasst von Sercan Ön. Beteiligte Einrichtung: Department of Medical Oncology, Ege University Faculty of Medicine, Ege University Hospital, Izmir, Turkey. sercan.on@ege.edu.tr. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
To the Editor, Asai-Sato and colleagues [1] recently presented important data on subsequent primary cancer (SPC) trends among 49,824 cervical cancer survivors across three Japanese registries.Analyzing second cancers in such a large group is a great contribution, and the authors deserve credit for collecting this long-term dataset.However, I would like to comment on a few methodological points that could help readers better understand these findings.First, I think the definition of synchronous tumors needs a brief explanation.The authors included cancers diagnosed on the exact same day as cervical cancer as SPCs, without applying a minimum waiting period.In routine cancer care, same-day diagnoses usually occur because the patient undergoes detailed scans during their initial staging work-up, rather than developing a new cancer over time [2].Even though a 6-month sensitivity analysis was provided, keeping these same-day cases in the main analysis can artificially raise the standardized incidence ratios (SIRs).Referring to established registry rules, such as the International Agency for Research on Cancer/International Association of Cancer Registries guidelines, would make these numbers much easier to interpret [3].Second, combining invasive cervical cancer with carcinoma in situ (CIS) creates some clinical confusion.Patients with CIS do not receive pelvic radiation or chemotherapy, they have a normal life expectancy, and they follow different check-up schedules.Mixing CIS with invasive disease can mask or weaken the actual risks linked to cancer treatments.Although the supplementary files contain subgroup data, presenting invasive cancer and CIS separately in the main text would give treating doctors much more useful guidance.
Autor:innen und Institutionen
- Department of Medical Oncology, Ege University Faculty of Medicine, Ege University Hospital, Izmir, Turkey. sercan.on@ege.edu.tr.
ORCID-Profile: Sercan Ön
Zitieren
APA
Ön, S. (2026). Comment of ‘Subsequent primary cancer incidence in cervical cancer survivors: insights from a comprehensive cohort study utilizing combined Japanese population-based cancer registries’. Journal of Gynecologic Oncology, 37. https://doi.org/10.3802/jgo.2026.37.e133
Vancouver
Ön S. Comment of ‘Subsequent primary cancer incidence in cervical cancer survivors: insights from a comprehensive cohort study utilizing combined Japanese population-based cancer registries’. Journal of Gynecologic Oncology. 2026;37. doi:10.3802/jgo.2026.37.e133
BibTeX
@article{n2026,
author = {Ön, Sercan},
title = {Comment of ‘Subsequent primary cancer incidence in cervical cancer survivors: insights from a comprehensive cohort study utilizing combined Japanese population-based cancer registries’},
journal = {Journal of Gynecologic Oncology},
year = {2026},
volume = {37},
doi = {10.3802/jgo.2026.37.e133}
}
EUVIMED